医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hoya Reports Second Quarter Results

2016年10月28日 PM08:14
このエントリーをはてなブックマークに追加


 

TOKYO

Hoya Corporation (TOKYO: 7741) today announced financial results for the second quarter ended September 30, 2016.

During the quarter, revenue of the HOYA Group decreased 11.8% year on year, to 114,865 million yen. Due to gains from the sales of securities, profit before tax amounted to 31,637 million yen, while profit for the quarter was 24,819 million yen, which were 6.6% and 8.6% lower, respectively, than in the same quarter last year.

In the Information Technology segment, sales of the mask blanks for semiconductors declined slightly due to the appreciation of the yen. Sales of photomasks for semiconductors and LCDs decreased because of the drop in production capacity owing to closure of the Kumamoto Plant following the Kumamoto earthquakes. Although the unit volume of glass substrates for hard disk drives began to rise, sales of imaging-related products decreased because of a decline in demand and the appreciation of the yen. As a result, sales of the IT segment as a whole decreased compared with the same quarter last year.

In the Life Care segment, sales of contact lenses and intraocular lenses held firm. Sales of eyeglass lenses increased on a local currency basis, mainly in the Americas; however, overall sales in this business decreased in yen terms because of the effects of the appreciation of the yen. Sales of endoscopes also expanded on a local currency basis in the Americas, Europe, and Asia, but decreased in yen terms due to the appreciation of the yen. As a result, sales of the Life Care segment as a whole declined compared with the same quarter last year.

For the six months ended September 30, 2016, revenues totaled 230,030 million yen, decreasing by 10.3% year-on-year. Pre-tax profit was 53,911 million yen and profit for the term was 42,797 million yen, decreasing by 16.8% and 15.7% respectively.

“We see some positive factors in the Life Care segment, in addition to intraocular lens business that continues double-digit growth and is building market share,” said Hiroshi Suzuki, president and chief executive officer of HOYA. “Eyeglass sales in the U.S. continued to grow, and sales in China recovered. In endoscopes business, the margin of decline due to U.S. regulatory issues diminished and sales showed improvement on a local currency basis.”

HOYA also announced the interim dividends of 30 yen per share of common stock.

 

Summary of Consolidated Financial Statement

(Millions of Yen: Rounded to the nearest million)
  Three months ended   Variance   Six months ended   Variance
  Sept./15   Sept./16 (%) Sept./15   Sept./16 (%)
Revenue 130,165 114,865 -11.8 256,403 230,030 -10.3
Profit before tax 33,858 31,637 -6.6 64,759 53,911 -16.8
Profit for the term 27,140 24,819 -8.6 50,790 42,797 -15.7
Basic earnings per share(yen)   65.15   63.42     120.40   108.62  

*Results are preliminary and unaudited.

 

The full reports are available at: www.hoya.com

About HOYA

Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company and the leading supplier of innovative high-tech and medical products. Hoya is active in the fields of healthcare and information technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, Hoya currently employs a multinational workforce of over 34,000 people. For more information, please visit http://www.hoya.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005406/en/

CONTACT

Hoya Group
Akiko Chiba, +81-3-6911-4824
Public Relation
HOYA-pr@hoya.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Vyome Presents on Development of Dual Action Rational Therapeutics (DARTs) to Treat Infections Caused by Antibiotic-Resistant Skin Opportunist Pathogens at Re-Entering Antibacterial Discovery and Development Summit 2016
  • CRISPRライセンシングのニーズに応えるMPEG LAイニシアチブ
  • 世界肺癌大会上呈报ABOUND数据,探索ABRAXANE®用于挑战性患者群体的安全性和有效性
  • Ajinomoto Is Awarded for the Contribution to Reduce Greenhouse Gas through Feed-Use L-Lysine
  • Ancillare宣布任命亚太区副总裁